NCT05154084 (RESECT) is a clinical trial of Performance feedback and education in Bladder Cancer, sponsored by British Urology Researchers in Surgical Training.

Who is sponsoring NCT05154084?

NCT05154084 is sponsored by British Urology Researchers in Surgical Training.

What drugs are being tested in NCT05154084?

Interventions in NCT05154084: Performance feedback and education.

What condition does NCT05154084 study?

NCT05154084 studies Bladder Cancer.

Is NCT05154084 still recruiting?

NCT05154084 is currently completed. Last updated 14 November 2023.

Last reviewed 2023-11-14 · How we verify

NCT05154084: RESECT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

RESECT: Improving Quality in TURBT Surgery.

Completed Last updated 14 November 2023

What this trial tests

trial testing Performance feedback and education in Bladder Cancer in 19,505 participants. Completed in 30 September 2023.

Timeline

19 April 2021

Primary endpoint
31 July 2023

30 September 2023

Quick facts

Lead sponsor	British Urology Researchers in Surgical Training
Status	Completed
Study type	OBSERVATIONAL
Enrollment	19,505
Start date	19 April 2021
Primary completion	31 July 2023
Estimated completion	30 September 2023
Sites	1 location across United Kingdom

Drugs / interventions tested

Performance feedback and education

Conditions studied

Bladder Cancer — all drugs for Bladder Cancer →

Sponsor

British Urology Researchers in Surgical Training

Who can join

16 and older, any sex, with Bladder Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Superficial bladder cancer, known as non-muscle-invasive bladder cancer (NMIBC), is the most common type of bladder cancer. It is expensive to manage and significantly impacts on patients' quality of life. This is because there is a high burden of recurrent disease after initial treatment, and need for long term surveillance for recurrence. The most important step in the diagnosis and treatment of NMIBC is the first surgical procedure called the transurethral resection of bladder tumour (TURBT). There is evidence that the quality of the TURBT operation, and the use of a single administration of bladder chemotherapy following the operation, can reduce cancer recurrence rates and progression to more invasive cancer. There is anecdotal evidence that the quality of TURBT surgery and the usage of intravesical chemotherapy varies widely between hospitals and thus may result in worse outcomes for some patients. The primary objective of the study is to determine if audit and feedback can improve the quality of TURBT surgery and if this reduces recurrence of NMIBC.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Audit, Feedback, and Education to Improve Quality and Outcomes in Transurethral Resection and Single-Instillation Intravesical Chemotherapy for Nonmuscle Invasive Bladder Cancer Treatment: Protocol for a Multicenter International Observational Study With an Embedded Cluster Rando
Gallagher K, Bhatt N, Clement K, Zimmermann E, et al · · 2023 · cited 3× · PMID 37318875 · DOI 10.2196/42254
Impact of audit and feedback on transurethral resection of bladder tumour quality: a monocentric post-completion evaluation of the RESECT trial.
Orecchia L, Gerardi M, Colalillo G, Leonardis F, et al · · 2026 · PMID 41919786 · DOI 10.1111/bju.70266
NS-AUA 2023 Annual Meeting Abstracts – Oncology – Bladder, Renal, Testes
Gaba F, Gallagher K, Bhatt N, Clement K, et al · · 2023
CUA 2023 Annual Meeting Abstracts - Podium Session 4: Oncology - Bladder/Kidney/Other Sunday, June 25, 2023 • 9:00-10:00.
· 2023 · PMID 37315271 · DOI 10.5489/cuaj.8407

Verify or expand the search:

Other recruiting trials for Bladder Cancer

Currently open trials in the same condition.

NCT07419295 — A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031) · Phase 3 · recruiting
NCT07322263 — Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC · Phase 2 · recruiting
NCT07420517 — Dutasteride in Patients With Low Grade Non-muscle Invasive Bladder Cancer · Phase 2 · recruiting
NCT07475403 — Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer · Phase 2 · recruiting
NCT07277413 — A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors · Phase 1 · recruiting

Other British Urology Researchers in Surgical Training trials

Trials by the same sponsor.

NCT07395037 — A Study of Ward Admissions for Haematuria · recruiting
NCT03548688 — Investigation and Detection of Urological Neoplasia in Patients Referred With Suspected Urinary Tract Cancer: · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05154084 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by British Urology Researchers in Surgical Training
Last refreshed: 14 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05154084.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing